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Abstract In the follow-up of patients treated for high
grade glioma, differentiation between progressive disease
(PD) and treatment-induced necrosis (TIN) is challenging.
The purpose of this study is to evaluate the diagnostic
accuracy of FDG PET for the differentiation between TIN
and PD after high grade glioma treatment. We retrospec-
tively identified patients between January 2011 and July
2013 that met the following criteria: age[18; glioma grade
3 or 4; treatment with radiotherapy or chemoradiotherapy;
new or progressive enhancement on post treatment MRI;
FDG PET within 4 weeks of MRI. Absolute and relative
(to contralateral white matter) values of SUVmax and
SUVpeak were determined in new enhancing lesions on
MRI. The outcome of PD or TIN was determined by
neurosurgical biopsy/resection, follow-up MRI, or clinical
deterioration. The association between FDG PET and
outcome was analyzed with univariate logistic regression
and ROC analysis for: all lesions, lesions[10,[15, and
[20 mm. We included 30 patients (5 grade 3 and 25 grade
4), with 39 enhancing lesions on MRI. Twenty-nine lesions
represented PD and 10 TIN. Absolute and relative values of
SUVmax and SUVpeak showed no significant differences
between PD and TIN. ROC analysis showed highest AUCs
for relative SUVpeak in all lesion sizes. Relative SUVpeak
for lesions [20 mm showed reasonable discriminative
properties [AUC 0.69 (0.41–0.96)]. FDG PET has reason-
able discriminative properties for differentiation of PD
from TIN in high grade gliomas larger than 20 mm.
Overall diagnostic performance is insufficient to guide
clinical decision-making.
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Introduction
High grade gliomas are the most common malignant pri-
mary brain tumors, with glioblastoma multiforme (GBM)
accounting for 15 % of intracranial neoplasms. Fewer than
10 % of GBM patients survive beyond a period of 5 years
[1]. Treatment of GBM typically involves neurosurgery
followed by radiotherapy with concomitant and adjuvant
chemotherapy [2]. In anaplastic gliomas (WHO grade 3),
most patients will receive radiotherapy, some with con-
comitant and adjuvant chemotherapy (temozolomide) or
post-radiotherapy chemotherapy (procarbazine-CCNU-
vincristine, PCV) [3]. In the follow-up of these patients, it
is essential to rapidly and accurately identify recurrent or
progressive tumor (progressive disease, PD). In neuro-on-
cological imaging, this has proven to be a continuing
challenge due to overlapping imaging characteristics of PD
and treatment-induced necrosis (TIN), also referred to as
pseudoprogression [4]. TIN causes new or increasing
contrast-enhancing lesion(s) on MRI within the original
high-dose radiation field. This strongly resembles the
radiological aspect of PD [5, 6]. TIN may be identified by
the spontaneous stabilization or regression of the contrast-
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enhancing lesion over time, requiring follow-up imaging.
This delays the diagnosis of PD causing delayed insight in
the ineffectiveness of chemotherapy, and thereby unnec-
essary continuation of treatment.
The most reliable method to confirm PD is tissue anal-
ysis after neurosurgical biopsy or resection. However, each
neurosurgical intervention carries the risks associated with
neurosurgery. In addition, false negative results may occur
due to sampling errors, especially in biopsies. As a result
the diagnosis is often based on non-invasive methods [7].
18F-FDG (FDG) PET has shown to be able to accurately
identify areas of active disease in brain tumors [8]. In
addition FDG uptake correlates with tumor grade and
aggressiveness [8, 9]. However, the use of FDG PET for
the differentiation between TIN and PD has remained
limited. The total number of case studies using FDG PET
for this purpose is small. In general, lesions that are sus-
picious for PD on MR imaging (MRI) that show increased
FDG uptake are likely to represent PD. When using FDG
PET for this purpose, low sensitivity is an important
problem. Small foci of PD may be hard to identify. In
recent years FDG PET imaging has shown great
improvement. The spatial resolution has increased dra-
matically and the possibility to co-register the FDG PET
images to the MRI has improved the diagnostic perfor-
mances of FDG PET in other fields of medicine [10–12].
The purpose of this study is to evaluate the diagnostic
accuracy of state-of-the art FDG PET for the differentiation
between TIN and PD in patients with high grade glioma.
Methods
Study design and patient selection
In this retrospective cohort study we identified all patients
treated for high grade glioma between January 2011 and
July 2013 that met the following inclusion criteria: (1) age
[18 years; (2) histologically proven WHO grade 3 or 4
glioma; (3) postoperative treatment with radiotherapy
(RTX) with or without additional chemotherapy; (4) new
or progressive enhancement on post treatment MRI; (5)
FDG PET imaging within 4 weeks of the MRI. Data on
age, sex, treatment type and time between RTX and MRI
were collected.
The study was approved by the institutional review
board.
Treatment protocol
Patients were treated according to international guidelines.
All GBM patients with a good clinical condition
(Karnofsky performance scale 70 or higher) and lack of
contra-indication were treated with radiotherapy, con-
comitant chemotherapy (temozolomide: 75 mg/m2/day for
42 days), and adjuvant chemotherapy (temozolomide: 6
4-weekly adjuvant cycles: 200 mg/m2/day, 5 days on,
23 days off). Radiotherapy consisted of 30 fractions of
2 Gy, using intensity modulated radiotherapy (IMRT).
Alternatively, GBM patients with high age and/or poor
clinical condition, who were eligible for treatment, usually
underwent a short schedule of radiotherapy (12 fractions of
3.5 Gy). Most patients with anaplastic glioma also under-
went radiotherapy 30 9 2 Gy, without chemotherapy.
After 2012, patients with anaplastic-oligodendroglial
tumors and co-deletion of 1p and 19q underwent PCV
chemotherapy after radiotherapy [13, 14].
Post radiotherapy MRI protocol
In all high grade glioma patients at our institution MRI
scans are performed within 4 weeks prior to radiotherapy.
In GBM patients who undergo temozolomide-based
chemoradiation, the first post-treatment MRI is obtained at
3–4 weeks after completion of the concomitant phase of
chemoradiotherapy; in the patients receiving radiotherapy
as monotherapy (both anaplastic gliomas and GBM), the
first post-treatment MRI follows 12–16 weeks after radio-
therapy. All MRIs were acquired at 1.5T (Philips Health-
care, Best, the Netherlands). The MRI protocol included
FLAIR, T1, gadolinium enhanced 3D T1, and DWI
sequences.
We identified cases of possible PD on the basis of
increased or new enhancement on post-radiotherapy T1
gadolinium enhanced images within the high-dose radia-
tion field.
PET-protocol
A 10-min static acquisition of the brain was acquired on a
PET/CT camera (Biograph TruePoint 40, Siemens
Healthcare) starting 30 after intravenous injection of
2 MBq/kg 18F-FDG. All patients fasted for at least 6 h
prior to imaging. A low-dose CT scan without contrast
enhancement was used for attenuation correction (120 kV,
40 mAs). PET images were reconstructed using, TOF,
point spread function and 4 iterations with 21 ordered
subsets after attenuation correction.
Imaging analysis (variables)
The initial MRI images were co-registered to the PET
images. Regions of interest (ROI) were drawn in the area of
new or increased enhancement shown on the MRI images
and in the contralateral white matter. Measurement of
SUVmax and SUVpeak were obtained in all ROIs. Relative
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values of SUVmax and SUVpeak were calculated as ratios
between the values in the enhancing lesion and the SUV-
mean of contralateral white matter [15].
Outcome
In this study, we included both patients with and without
adjuvant temozolomide treatment after the initial FDG PET.
The presence of PD or TIN was determined by neuro-
surgical biopsy/resection, follow-up MRI, or clinical
deterioration following the initial MRI.
On follow-up MRI, PD was defined according to RANO
criteria as further increase of enhancing lesion(s) on con-
trast enhanced T1 images, adding up to an increase of more
than 25 % in the sum of the products of perpendicular
diameters compared to baseline (pre-radiotherapy) MRI
[16, 17]. TIN was defined as any new enhancing lesion on
contrast enhanced T1 that remained stable, decreased or
disappeared after 12 weeks [17].
In cases where the patient underwent a second biopsy/
resection of enhancing tissue, the final outcome is deter-
mined by the histological diagnosis (TIN or PD).
Finally, PD could also be diagnosed on the basis of
clinical deterioration, if no follow-up imaging or tissue
diagnosis was obtained. The diagnosis ‘clinical PD’ was
based on the occurrence of clinical-neurological deterio-
ration shortly (\12 weeks) after the MRI corresponding to
the location of the lesion with increasing enhancement.
Statistical analysis
The association between potential predictor variables and
the outcome, PD, was analyzed by means of univariate
logistic regression. Since the accuracy of FDG PET is
greatly dependent on lesion size [18, 19], analyses were
done separately for: (1) all lesions; (2) lesions larger than
10 mm on MRI; (3) lesions larger than 15 mm; (4) lesions
larger than 20 mm. For each variable the odds ratio (OR)
with the 95 % confidence interval (95 % CI) was deter-
mined. ROC curves were created for all variables. The AUC
with 95 % CI of all ROC curves was determined. For the
variable with the highest AUC the sensitivity, specificity,
positive predictive value (PPV) and negative predictive
value (NPV) were determined for the cutoff value with
optimal predictive properties. Statistical computations were
carried out with SPSS 19.0 (IBM Corporation, NY, USA).
Results
Thirty-seven patients met the inclusion criteria. In 7
patients a final diagnosis of either PD or TIN could not be
obtained. Three of these patients died shortly after the
initial imaging. The other 4 patients were treated with
additional anti-tumor therapy (mostly chemotherapy) after
the initial imaging showed increased enhancement. Since
further follow-up imaging showed stable or decreased
enhancement, it was impossible to differentiate a positive
effect of the treatment on PD from spontaneous regression
of TIN in these 4 patients.
The characteristics of the remaining 30 patients are
summarized in Table 1. Five patients had grade 3 glioma
and 25 patients grade 4 glioma. Treatment consisted
radiotherapy and temozolomide in 25 patients, radiother-
apy only in 4 patients, and a combination of radiotherapy,
carmustine (BCNU) and dibromodulcitol (as part of a
clinical trial) in 1 patient. The median time between
radiotherapy and the initial MRI was 10 months (range
3–101). The median time between this MRI and the FDG
PET was 6 days (range -5 to 27 days). The 30 patients had
a total of 39 enhancing lesions on MRI. 29 lesions repre-
sented PD and 10 TIN. The outcome was determined with
MRI follow-up in 24 lesions, biopsy in 12 lesions and by
the clinical course in 3 lesions. The average lesion diameter
on MRI for PD was not significantly different from TIN
(29.8 vs 30.2 mm, mean difference of 0.44 mm with a
95 %-CI of -14.3 to 13.8).
The PET findings are summarized in Table 2. Absolute
and relative values of SUVmax and SUVpeak showed no
significant differences between PD and TIN. ROC analysis
showed highest AUCs for relative SUVpeak in all lesion
sizes (Fig. 1). The use of relative SUVpeak for lesion
larger than 15 and 20 mm showed reasonable discrimina-
tive properties with AUCs of 0.68 (0.45–0.90) and 0.69
(0.41–0.96) respectively. For lesions larger than 20 mm a
threshold value for the relative peak enhancement of 2.26
yielded a sensitivity of 0.76 (0.56–0.97), a specificity of
0.83 (0.54–1.13), a negative predictive value of 0.56
(0.23–0.88) and a positive predictive value of 0.93
(0.79–1.06) for PD.
Figure 2 shows illustrative cases with true positive, false
positive, true negative, and false positive FDG PET
findings.
Discussion
Our results show reasonable discriminative properties of
FDG PET for lesions larger than 20 mm. However, adding
smaller lesion clearly makes FDG PET for the differenti-
ation between PD and TIN unreliable. The differentiation
between PD and TIN with FDG PET therefore remains
difficult.
A recent meta-analysis of the discriminative properties
of FDG PET for PD in high-grade glioma patients showed
sensitivities ranging between 0.18 and 1.00 with a
J Neurooncol (2015) 125:167–175 169
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Table 1 Patients characteristics




















1 79 GBM 4 RT 5 25 6 6.8 3.3 4.8 2.4 PD Clinical-FU
2 62 GBM 4 RT/TMZ 18 11 25 14.5 5.1 10.6 3.7 PD MRI-FU
18 15 25 7.8 2.7 5.4 1.9 PD MRI-FU
18 5 25 5.5 1.9 4.2 1.5 PD MRI-FU
3 34 OA 3 RT 101 12 15 8.7 3.7 3.1 1.3 PD Tissue
4 31 AA 3 RT 20 35 8 17.7 9.6 11.8 6.4 PD MRI-FU
20 6 8 21.6 11.7 7.6 4.1 PD MRI-FU
5 56 GBM 4 RT/TMZ 11 21 4 8.5 3.1 3.8 1.4 PD MRI-FU
6 47 GBM 4 RT/TMZ 8 57 7 6.7 3.0 5.9 2.7 PD Tissue
7 61 GBM 4 RT/TMZ 7 26 -1 5.4 2.2 4.8 2.0 PD Tissue
8 68 GBM 4 RT/TMZ 4 35 21 7.8 2.8 6.0 2.2 TIN MRI-FU
9 55 GBM 4 RT/TMZ 42 9 6 7.6 3.2 5.1 2.1 PD Tissue
10 59 GBM 4 RT/TMZ 21 10 7 9.5 4.8 6.5 3.3 TIN MRI-FU
11 49 GBM 4 RT/TMZ 4 16 -5 5.8 2.6 4.7 2.1 TIN Tissue
12 35 GBM 4 RT 4 29 6 19.2 10.2 12.9 6.9 PD MRI-FU
13 48 AA 3 RT/BCNU/
dibromo-
dulcitol
20 9 27 7.7 3.6 4.7 2.2 TIN MRI-FU
20 22 27 6.7 3.1 4.5 2.1 TIN MRI-FU
14 49 GBM 4 RT/TMZ 4 55 3 8.4 4.2 6.2 3.1 PD Tissue
4 56 3 10.4 4.4 7.6 3.2 PD Tissue
15 53 GBM 4 RT/TMZ 10 14 2 8.2 3.8 6.2 2.9 PD Clinical-FU
16 64 GBM 4 RT/TMZ 6 72 7 9.2 3.7 8.0 3.2 PD Tissue
17 50 GBM 4 RT/TMZ 10 31 7 8.3 4.1 6.6 3.3 PD Tissue
18 67 GBM 4 RT/TMZ 4 55 8 7.3 2.9 5.3 2.1 TIN MRI-FU
19 59 GBM 4 RT/TMZ 7 34 5 8.9 3.1 7.4 2.6 PD Tissue
20 56 GBM 4 RT/TMZ 8 17 7 13.7 4.4 11.6 3.7 PD MRI-FU
21 41 AA 3 RT/TMZ 33 20 3 6.3 2.5 3.1 1.2 PD MRI-FU
22 58 AA 3 RT/TMZ 13 47 10 7.3 2.7 5.2 2.1 PD MRI-FU
13 32 10 6.2 3.6 4.8 2.5 PD MRI-FU
13 17 10 6.2 2.7 4.5 1.9 PD MRI-FU
23 57 GBM 4 RT/TMZ 15 29 4 14.6 4.7 11.9 3.8 PD Tissue
24 63 GBM 4 RT/TMZ 3 60 6 8.5 3.7 6.6 2.9 PD MRI-FU
25 66 GBM 4 RT/TMZ 12 64 15 10.4 4.6 8.6 3.8 PD Clinical-FU
26 50 GBM 4 RT/TMZ 5 51 7 7.6 2.9 4.4 1.7 TIN MRI-FU
5 20 7 7.5 2.8 4.3 1.6 TIN MRI-FU
27 51 GBM 4 RT/TMZ 23 14 3 3.8 1.9 2.1 1.0 PD Tissue
28 56 GBM 4 RT/TMZ 12 48 5 8.9 3.4 5.5 2.1 TIN MRI-FU
24 36 13 22.2 9.8 14.9 6.6 TIN MRI-FU
29 57 GBM 4 RT/TMZ 6 37 5 5.9 2.5 4.2 1.8 PD Tissue
30 56 GBM 4 RT/TMZ 13 13 5 7.0 2.7 3.0 1.2 PD MRI-FU
Clinical-FU clinical follow-up, MRI-FU follow-up MRI, GBM glioblastoma multiforme, PD progressive disease, RT radiotherapy, TIN treat-
ment-induced necrosis, Tissue tissue diagnosis (biopsy or resection), TMZ temozolomide, Relative SUVmax SUVmax lesion/SUVmean normal
contralateral white matter, Relative SUVpeak SUVpeak lesion/SUV mean normal contralateral white matter
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summarized sensitivity of 0.79 (95 % CI 0.67–0.88) [20].
Specificities ranged between 0.25 and 1.00 with a sum-
marized specificity of 0.70 (95 % CI 0.50–0.84) [20].
These values are similar to our findings. The maximum
number of patients in the studies selected for the meta-
analysis was 44 with an average of 22 patients [21], making
Table 2 Discriminative
properties of 18F-FDG PET for
progressive disease and
treatment induced necrosis
Lesions (PD/TIN) PET parameter PD TIN p value OR (95 % CI) AUC (95 % CI)
All (29/10) SUVmax 9.4 9.1 0.85 1.02 (0.86–1.21) 0.52 (0.32–0.72)
Relative SUVmax 4.1 3.9 0.72 1.05 (0.75–1.48) 0.54 (0.34–0.74)
SUVpeak 6.5 6.1 0.73 1.05 (0.81–1.36) 0.57 (0.37–0.76)
Relative SUVpeak 2.8 2.6 0.78 1.11 (0.64–1.95) 0.56 (0.36–0.75)
[10 mm (26/8) SUVmax 9.2 9.2 0.97 1.00 (0.82–1.21) 0.55 (0.32–0.77)
Relative SUVmax 3.9 3.8 0.86 1.04 (0.69–1.58) 0.60 (0.38–0.81)
SUVpeak 6.6 6.2 0.78 1.04 (0.80–1.36) 0.58 (0.36–0.80)
Relative SUVpeak 2.80 2.54 0.67 1.15 (0.62–2.11) 0.60 (0.38–0.81)
[15 mm (20/8) SUVmax 9.43 9.23 0.92 1.01 (0.83–1.23) 0.55 (0.31–0.79)
Relative SUVmax 4.12 3.78 0.72 1.09 (0.71–1.66) 0.63 (0.40–0.86)
SUVpeak 7.00 6.19 0.54 1.10 (0.82–1.49) 0.64 (0.40–0.87)
Relative SUVpeak 3.04 2.54 0.44 1.32 (0.66–2.64) 0.68 (0.45–0.90)
[20 mm (17/6) SUVmax 9.55 10.09 0.81 0.97 (0.79–1.20) 0.51 (0.24–0.78)
Relative SUVmax 4.28 4.14 0.90 1.03 (0.67–1.57) 0.63 (0.36–0.90)
SUVpeak 7.11 6.75 0.81 1.04 (0.75–1.44) 0.61 (0.33–0.89)
Relative SUVpeak 3.17 2.77 0.60 1.22 (0.60–2.50) 0.69 (0.41–0.96)
PD progressive disease, TIN treatment-induced necrosis, OR odds ratio, AUC area under the curve
Fig. 1 ROC curves by lesion
size
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our series relatively large. In the meta-analysis only few
studies used treatment strategies that are consistent with the
currently used treatment protocols (i.e. temozolomide-
based multimodality therapy) [20]. In our study 81 % of
the patients received a combination of radiotherapy and
temozolomide.
The use of FDG PET for the differentiation of PD from
TIN is hampered by several features. Firstly conditions like
status epilepticus increase glucose metabolism in parts of
the brain, thereby mimicking tumor activity (Fig. 2g–i,
patient 6). Secondly, glucose metabolism may be increased
by radiation induced inflammation, resulting in false-pos-
itive findings for PD. Thirdly, despite continuing
improvement of spatial resolution PET imaging still has
low sensitivity for smaller lesions. This is also illustrated
by our results that show increasing sensitivity with
increasing lesion size. The co-registration of the PET
images with MRI has significantly improved lesion detec-
tion. However, our results show that FDG PET seems to be
insufficient to differentiate between PD and TIN in small
lesions. Further improvement of the resolution can be
expected with the development of combined PET/MR
systems and new detectors.
To improve the detection of tumor with PET other
tracers are being investigated. Since progressing tumors
exhibit increased amino acid transport, amino acid analogs,
such as O-2-18F-fluoroethyl-L-tyrosine (18F–FET); 3,4-di-
hydroxy-6–18F-fluoro-L-phenylalanine (18F-FDOPA); and
L-methyl-11C-methionine (11C-MET) seem to be interest-
ing candidates for the differentiation between TIN and PD
[7, 22]. These tracers show lower uptake in normal cortex
making more accurate detection possible. A recent meta-
analysis evaluating the use of 11C-MET PET for the
detection of glioma recurrence showed high sensitivity
(0.87) and specificity (0.81) [21].
MRI-based imaging techniques, such as perfusion
weighted imaging [23–26], diffusion weighted imaging
[27] and MR spectroscopy [26, 28], and other imaging
techniques like SPECT [29], and dynamic contrast
enhanced CT [30] also have reasonable discriminative
properties for PD and TIN. However, none of the tech-
niques are sufficiently reliable to completely guide clinical
decision-making in all cases. Thereby multimodal imaging
may be needed to provide stronger diagnostic information
[4, 7]. Combined PET/MRI-scanning, with different PET
tracers as well as combination of advanced MRI-tech-
niques with FDG may prove useful and should be further
studied in the future. However, mixed lesions containing
both TIN and PD will most likely remain challenging for
any combination of imaging techniques.
Due to several limitations our result need to be inter-
preted with caution. Firstly, we included only 30 patients
with 39 lesions in our analysis. In the analysis with lesions
larger than 20 mm only 23 lesions were included of which
only 6 lesions proved to be TIN. Secondly, the use of
follow-up imaging as a gold standard for PD is difficult.
High grade glioma has a very high progression rate
exceeding 90 % within 5 years in GBM. This implies that
the longer you follow the patient, the more likely it is that
the patient will develop PD. This progression may however
not have been present at the time of the diagnostic dilemma
of differentiating TIN from PD. The only true gold stan-
dard would be a representative (i.e. sufficiently large) tis-
sue specimen, taken exactly from the enhancing area on
MRI that was suspicious of PD, at the time of first pre-
sentation. This poses an ethical problem, since neurosur-
gical biopsy carries an important risk of complications. In
our study only one-third of the patients underwent neuro-
surgical biopsy. Thirdly, the time between FDG PET and
MRI was relatively long in some patients. Again this may
have resulted in PD having occurred after the initial
imaging. Fourthly, the retrospective study design resulted
in the exclusion of several patients. We excluded all
patients (n = 4) that were suspected of having PD based on
the FDG PET images and therefore received additional
treatment. The inhibiting effect of the treatment on further
tumor growth could not be differentiated from non-pro-
gressive TIN already present at the start of the additional
treatment. A prospective analysis is however difficult since
patients that are suspected to have PD ought to receive
additional treatment. Fifthly, selection bias has most likely
occurred. FDG PET is not a standard procedure in the
follow-up of high grade glioma patients in our institution.
Only cases with hard to interpret MRI findings are likely to
receive FDG PET. Although the effect of this selection on
the results is difficult to assess, the selection bias may have
contributed to the limited value of FDG PET in our study
population. However, this selection forms a good repre-
sentation of the population of interest, since advanced
imaging for differentiation of TIN from PD is most
bFig. 2 Four illustrative cases. a–c True positive FDG PET (patient 4)
with an anaplastic astrocytoma presenting with a new enhancing
lesion of 35 mm 20 months after radiotherapy. The lesion showed
increased FDG uptake and proved to represent progressive disease
(PD) on follow-up MRI. d–f False positive FDG PET (patient 28)
with glioblastoma multiforme (GBM) presenting with a new enhanc-
ing lesion of 48 mm 12 months after chemoradiotherapy. Increased
FDG uptake was seen laterally in the lesion. The lesion proved to
represent treatment induced necrosis (TIN) on follow-up MRI. The
increased FDG uptake may have been caused by status epilepticus.
g–i False negative FDG PET (patient 6) with GBM presenting with a
new enhancing lesion of 57 mm 8 months after chemoradiotherapy.
The lesion did not show increased FDG uptake. Tissue analysis after
neurosurgical biopsy showed PD. j–l True negative FDG PET (patient
18) with GBM presenting with a new enhancing lesion of 55 mm
4 months after chemoradiotherapy. The lesion did not show increased
FDG uptake and proved to represent TIN on follow-up MRI
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relevant in patients with ambiguous findings on conven-
tional MR imaging.
In conclusion, we evaluated the diagnostic properties of
advanced FDG PET imaging with MRI-coregistration for
the differentiation between TIN from PD in the follow-up
of irradiated high-grade gliomas. Our data confirm the
results from previous studies, showing that FDG PET
provides some degree of differentiation between TIN and
PD. However, in small lesions (\20 mm diameter) the
diagnostic performance of FDG PET is poor and in larger
lesions the performance is only reasonable. This is most
likely not sufficient to fully guide clinical decision-making.
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